New MRI dye aims to sharpen detection of dangerous prostate cancers
NCT ID NCT06262139
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new MRI contrast agent called MT218 that targets prostate cancer cells. The goal is to see if it can more clearly identify aggressive tumors (Gleason score 8-10) compared to standard MRI scans. The study will enroll 12 men scheduled for prostate removal surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT218 injection (a targeted MRI contrast agent)
What this could lead to
If successful, this could lead to a more accurate MRI scan that better identifies aggressive prostate cancers, potentially reducing unnecessary biopsies.
What could go wrong
This is a very early, small study (12 people) focused on safety and dosing. The contrast agent may not work as hoped, and results may not apply to all prostate cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MRI SCAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States